Evidence map›Paper›PMID 37154156›Full record

ArticleJCI insight2023

ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone.

Margaret C Costanzo, Dominic Paquin-Proulx, Alexandra Schuetz, Siriwat Akapirat, Zhanna Shubin, Dohoon Kim, Lindsay Wieczorek, Victoria R Polonis, Hung V Trinh, Mangala Rao and 25 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 9 institutions in 3 countries.

Margaret C CostanzoThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Dominic Paquin-ProulxThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Alexandra SchuetzHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Siriwat AkapiratArmed Forces Research Institute for Medical Sciences, Bangkok, Thailand.
Zhanna ShubinThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Dohoon KimThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Lindsay WieczorekThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Victoria R PolonisThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Hung V TrinhThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Mangala RaoThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Hanna AneniaThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Michael D BarreraThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Jacob BoeckelmanThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Barbara NailsThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Pallavi ThapaThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Michelle ZemilThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Carlo SacdalanSEARCH, Institution of HIV Research and Innovation, Bangkok, Thailand.
Eugene KroonSEARCH, Institution of HIV Research and Innovation, Bangkok, Thailand.
Boot KaewboonArmed Forces Research Institute for Medical Sciences, Bangkok, Thailand.
Somporn TipsukArmed Forces Research Institute for Medical Sciences, Bangkok, Thailand.
Surat JongrakthaitaeArmed Forces Research Institute for Medical Sciences, Bangkok, Thailand.
Sanjay GurunathanSanofi Pasteur, Swiftwater, Pennsylvania, USA.
Faruk SinangilGlobal Solutions for Infectious Diseases, South San Francisco, California, USA.
Jerome H KimInternational Vaccine Institute, Seoul, South Korea.
Merlin L RobbThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Julie A AkeThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Robert J O'ConnellThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Punnee PitisutthithumMahidol University, Bangkok, Thailand.
Sorachai NitayaphanArmed Forces Research Institute for Medical Sciences, Bangkok, Thailand.
Suwat ChariyalertsakRIHES, Chiang Mai, Thailand.
Michael A EllerThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Nittaya PhanuphakSEARCH, Institution of HIV Research and Innovation, Bangkok, Thailand.
Sandhya VasanThe US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
RV306
RV328 study groups
Henry M. Jackson Foundation · USArmed Forces Research Institute of Medical Science · THHIV Netherlands Australia Thailand Research Collaboration · THWalter Reed Army Institute of Research · USChiang Mai University · THGlobal Solutions for Infectious Diseases · USInternational Vaccine Institute · KRMahidol University · THSanofi (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The RV144 phase III vaccine trial demonstrated that ALVAC-HIV and AIDSVAX B/E administration over 6 months resulted in 31% efficacy in preventing HIV acquisition, while administration of AIDSVAX B/E alone in both VAX003 and VAX004 studies failed to show efficacy. In this study, we aimed to understand the impact of ALVAC-HIV on the development of cellular, humoral, and functional immune responses compared to the administration of AIDSVAX B/E alone. ALVAC-HIV in combination with 3 doses of AIDSVAX B/E significantly increased CD4+ HIV-specific T cell responses, polyfunctionality, and proliferation compared with 3 doses of AIDSVAX B/E alone. Additionally, Env-specific plasmablasts and A244-specific memory B cells were identified with a significantly higher magnitude in the group that received ALVAC-HIV. Subsequently, data revealed increased magnitude of plasma IgG binding to and avidity for HIV Env in participants who received ALVAC-HIV compared with 3 doses of AIDSVAX B/E alone. Lastly, levels of the Fc-mediated effector functions antibody-dependent cellular cytotoxicity, NK cell activation, and trogocytosis were significantly increased in participants who received ALVAC-HIV compared with those receiving AIDSVAX B/E alone. Taken together, these results suggest that ALVAC-HIV plays an essential role in developing cellular and humoral immune responses to protein-boosted regimens relative to protein alone.

Indexed as

HIV-1HIV InfectionsAIDS VaccinesHIV AntibodiesHumansImmunity, HumoralVaccinationAIDS VaccinesAIDSVAXHIV AntibodiesAIDS/HIVAIDS vaccine

Identifiers

PMID37154156
PMCPMC10243797
OpenAlexW4375955666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.